Search

Manufacturers must look to ease the headaches associated with the manufacture of mRNA-based products.

Virus-based vaccines were the first foray into immunization, but the field has had to move on and embrace new approaches.

With new vaccines come new challenges – and the need for new tools. Can mass spectrometry solve the problem of impurities?

Could mRNA vaccine be the flu interventions of tomorrow?

As we transition into the endemic phase of the pandemic, companies will have to consider how their mRNA products will be housed and stored.

Pfizer and BioNTech claim their two-dose COVID-19 mRNA vaccine (BNT162b2) is more than 90 percent effective.

Experts from Sartorius give advice on the next generation processes and facilities for mRNA manufacture.

How can our knowledge of mRNA vaccine development influence our Industry 4.0 journeys?

The latest issue of The Bioprocess Curator included a lot of interesting news about vaccines. In case you missed it, here's some of the top stories.

In our second C+G Champions installment, we ask industry leaders in the cell and gene field to answer key questions about the industry.